Table 3 Association between antigen specific human polyomavirus (HPyV) antibody levels and incident lung cancer, adjusted for matching variables

MCV^e VP1^f

1.00 (0.92–1.09)

0.951

 1

5.03

Referent

 2

8.50

0.67 (0.38–1.17)

0.163

 3

9.74

0.80 (0.49–1.31)

0.372

 4

12.57

0.90 (0.37–2.17)

0.810

MCV^e ST-Ag^g

0.97 (0.88–1.08)

0.623

 1

0.02

Referent

 2

0.05

1.01 (0.58–1.76)

0.985

 3

0.25

0.70 (0.40–1.22)

0.209

 4

4.12

0.85 (0.48–1.48)

0.553

KIV^h VP1^g

1.04 (0.92–1.17)

0.532

 1

6.92

Referent

 2

8.65

1.07 (0.61–1.88)

0.821

 3

9.32

1.64 (0.94–2.89)

0.089

 4

10.81

1.44 (0.82–2.52)

0.206

KIV^h ST-Ag^g

0.99 (0.90–1.10)

0.878

 1

0.02

Referent

 2

0.22

1 .00 (0.58–1.75)

0.991

 3

3.00

0.72 (0.41–1.27)

0.260

 4

4.43

1.13 (0.65–1.98)

0.652

WUVⁱ VP1^g

1.20 (0.96–1.51)

0.112

 1

8.16

Referent

 2

8.86

1.34 (0.77–2.36)

0.305

 3

9.34

1.15 (0.65–2.01)

0.643

 4

10.13

1.47 (0.84–2.58)

0.182

WUVⁱ ST-Ag^g

1.02 (0.91–1.14)

0.734

 1

0.02

Referent

 2

0.07

0.95 (0.55–1.67)

0.871

 3

2.40

0.83 (0.47–1.45)

0.522

 4

4.04

1.02 (0.58–1.78)

0.951